Vertex Pharmaceuticals saw its share price rise by approximately 14% in the last quarter, a significant move considering the broader market's recent 1% decline. The company's legal challenges ...

Investors eye Vertex’s Q1 for Alyftrek and Journavx momentum amid Trikafta’s international headwinds. Vertex stock shows a bullish technical bias despite recent pullback and mixed short-term ...

As previously reported, Cantor Fitzgerald assumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and a price target of $535, up from $480. Vertex remains well-positioned with ...

She reiterated her buy recommendation on Vertex stock, and kept her $583-per-share price target intact. According to reports, Merle's update was based on surveys with medical professionals ...

Guyana’s oil output took a dip in March, sliding to 627,000 barrels per day (bpd) from February’s 648,000 bpd, a new report from Reuters shows. That puts first-quarter production at a still ...

Guyana is committed to ensuring legal recognition of Indigenous Peoples’ land ownership in accordance with the relevant United Nations Declaration and will continue in this regard despite any ...

ToolGen, Inc. a global leader in genome editing technology, announced that it has filed a patent infringement lawsuit in the United Kingdom against Vertex Pharmaceuticals and its commercial ...

Guyana’s wait to win the Cricket West Indies (CWI) U-15 Championship, unfortunately, will continue for another edition as they lost their final match against the undefeated defending champion ...

With a market cap of $122.6 billion, Vertex Pharmaceuticals Incorporated (VRTX) operates as a global biotechnology company that develops and commercializes therapies for treating cystic fibrosis (CF).

Japanese company Modec has confirmed the award of a contract to develop a large floating production, storage and offloading vessel for ExxonMobil’s Hammerhead oil project offshore Guyana.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...